Eventide Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Eventide Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22M	Hold	225,261	–	–	0.29%	103
2026 Q1	$18.9M	Buy	+225,261	New	+$13M	0.31%	106
2021 Q1	–	Sell	-62,500	Closed	-$7.84M	–	161
2020 Q4	$7.84M	Sell	62,500 -84,978	-58%	-$9.63M	0.12%	115
2020 Q3	$16M	Hold	147,478	–	–	0.31%	89
2020 Q2	$17.7M	Buy	147,478 +35,625	+32%	+$5.02M	0.39%	73
2020 Q1	$11.2M	Sell	111,853 -100,265	-47%	-$18.6M	0.36%	80
2019 Q4	$51.5M	Buy	212,118 +27,403	+15%	+$5.12M	1.45%	23
2019 Q3	$30.3M	Sell	184,715 -33,737	-15%	-$6.41M	1%	35
2019 Q2	$50.8M	Buy	218,452 +26,562	+14%	+$6.57M	1.54%	19
2019 Q1	$49.7M	Buy	191,890 +26,214	+16%	+$4.52M	1.71%	15
2018 Q4	$14.8M	Buy	165,676 +25,795	+18%	+$3.52M	0.66%	54
2018 Q3	$26.3M	Hold	139,881	–	–	0.96%	36
2018 Q2	$29.5M	Buy	+139,881	New	+$31.6M	1.22%	34

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Eventide Asset Management's DNTH Position: Q2 2026 in Review

Eventide Asset Management held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 225,261 shares worth $22M. The position accounts for 0.29% of the portfolio, ranked #103.

Eventide Asset Management first reported a position in DNTH in Q2 2018 and has held it in 13 quarters since. The position peaked at $51.5M in Q4 2019. 268 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Eventide Asset Management held 225,261 shares of Dianthus Therapeutics worth $22M as of Q2 2026.
Eventide Asset Management left its Dianthus Therapeutics share count unchanged in Q2 2026.
Dianthus Therapeutics made up 0.29% of Eventide Asset Management's portfolio in Q2 2026, its #103 holding.
Eventide Asset Management first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 13 quarters since.
Eventide Asset Management's Dianthus Therapeutics position peaked at $51.5M in Q4 2019.
268 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.